It has been recommended that all transplant recipients undergo a tuberculin skin test (TST)
before transplantation. However, the ability of TST to diagnose latent tuberculosis infection
(LTBI) in transplant candidates has been reported to be suboptimal because of high rates of
false-negative and false-positive results. The enzyme-linked immunospot assay (ELISPOT)
detecting interferon-gamma secreting T-cells for diagnosing tuberculosis infection gave
promising results in immunocompromised patients as well as in immunocompetent patients. The
investigators will perform a randomized, open-label, prospective trial of isoniazid (INH)
prophylaxis based on ELISPOT assay for LTBI in renal transplant recipients.